India,
March 2018
India can claim with some degree of force to be ‘the pharmacy to the world.’ Not only are Indian medicines consumed in the US and EU, but enterprising Indian companies are increasingly looking towards huge underserved developing markets across the globe.
Furthermore, Indian companies are moving into the field of biologics; a handful of Indian biosimilars having already been approved in highly-regulated international markets. Multinationals are still being drawn to India too, helped by incentivising policies such as Prime Minister Modi’s ‘Make in India’ initiative, as well as the enduring draw of the huge population and unmet medical need within the Indian domestic market.
India can claim with some degree of force to be ‘the pharmacy to the world.’ Not only are Indian medicines consumed in the US and EU, but enterprising Indian companies are increasingly looking towards huge underserved developing markets across the globe.
Furthermore, Indian companies are moving into the field of biologics; a handful of Indian biosimilars having already been approved in highly-regulated international markets. Multinationals are still being drawn to India too, helped by incentivising policies such as Prime Minister Modi’s ‘Make in India’ initiative, as well as the enduring draw of the huge population and unmet medical need within the Indian domestic market.
